Skip to content
10-Q

Quarterly Report

ARGOS THERAPEUTICS INC

0001171843-17-006843

← back to feed
Filed
Nov 9, 2017 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2017 · Nov 3, 2017 87.88M sh
Long Term Debt Q3 2017 · Sep 30, 2017 $15.76M
Long Term Debt Q3 2017 · Dec 31, 2016 $18.67M
Stockholders Equity Q3 2017 · Sep 30, 2017 −$16.97M
Stockholders Equity Q3 2017 · Dec 31, 2016 $6.17M
Current Liabilities Q3 2017 · Sep 30, 2017 $9.57M
Current Liabilities Q3 2017 · Dec 31, 2016 $30.61M
Current Assets Q3 2017 · Sep 30, 2017 $21.86M
Current Assets Q3 2017 · Dec 31, 2016 $55.5M
Total Assets Q3 2017 · Sep 30, 2017 $25.73M
Total Assets Q3 2017 · Dec 31, 2016 $97.2M
Revenue Q3 2017 · Sep 30, 2017 $53.5K
Revenue Q3 2017 · Sep 30, 2017 $228.45K
Revenue Q3 2017 · Sep 30, 2016 $146.76K
Revenue Q3 2017 · Sep 30, 2016 $781.83K
Capex Q3 2017 · Sep 30, 2016 $10.04M
Operating Cash Flow Q3 2017 · Sep 30, 2016 −$31.46M
Cash And Equivalents Q3 2017 · Sep 30, 2016 $69.28M
Cash And Equivalents Q3 2017 · Dec 31, 2015 $6.16M
Sga Expense Q3 2017 · Sep 30, 2016 $3.01M
Sga Expense Q3 2017 · Sep 30, 2016 $9.38M
Rd Expense Q3 2017 · Sep 30, 2016 $9.34M
Rd Expense Q3 2017 · Sep 30, 2016 $28.01M
Net Income Q3 2017 · Sep 30, 2016 −$12.25M
Net Income Q3 2017 · Sep 30, 2016 −$37.67M
Operating Income Q3 2017 · Sep 30, 2016 −$12.2M
Operating Income Q3 2017 · Sep 30, 2016 −$36.6M